시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 공막염 시장 보고서(2025년)
Scleritis Global Market Report 2025
상품코드 : 1720890
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,527,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,434,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,341,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

공막염 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간의 증가는 눈 관련 건강 상태의 유병률 증가, 안구 건강에 대한 인식 증가, 의료비 지출 증가, 안과 연구 확대, 개인 맞춤형 의학에 대한 수요 증가, 그리고 새로운 치료 옵션 개발에 기인할 수 있습니다. 주요 동향으로는 표적 생물학적 요법의 개발, 면역 억제제 제제의 진보, 화상 기술의 혁신, 저침습 진단 툴의 채용, 맞춤형 의료 어프로치의 통합, 약물전달 시스템의 개선, AI 주도의 진단 및 치료 계획 솔루션 등을 들 수 있습니다.

자가면역 질환의 유병률 증가는 공막염 시장의 확대를 촉진할 것으로 예측됩니다. 자가면역 질환의 증가는 유전적 소인, 환경 영향, 라이프 스타일의 변화 및 진단 의식의 향상으로 인한 것입니다. 예를 들어, 2024년 11월 독일에 본사를 둔 조직인 Versorgungsatlas.de는 2022년 보험 가입자 7,324만 1,305명 중 630만 4,340명이 적어도 하나의 자가면역질환으로 진단되었다고 보고했으며, 이는 8.61%의 원병유병률(raw prevalence rate)에 해당한다고 보고했습니다.

공막염 시장의 주요 기업은 염증에 대처하고 비침습적인 치료 옵션을 제공하기 위해 특수 점안약 등의 선진 치료를 개발하고 있습니다. Entod Pharmaceuticals는 인도와 세계에서 CYCLOTEARS 점안약을 출시했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Scleritis is a condition characterized by inflammation of the sclera, the white part of the eye. It is commonly linked to autoimmune diseases and can lead to severe eye pain, redness, and potential vision impairment if left untreated. Proper diagnosis and treatment of scleritis are essential to prevent long-term eye damage. Early medical intervention helps lower the risk of complications, including vision loss.

The primary types of scleritis include anterior scleritis, posterior scleritis, and other forms. Anterior scleritis occurs when the front portion of the sclera, the eye's outer white layer, becomes inflamed, resulting in redness, pain, and swelling around the eyes. Treatment options include medications, surgical procedures, and other therapies. The condition is addressed through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. Additionally, scleritis treatment is provided in healthcare settings such as hospitals, specialty clinics, home healthcare, and other end-user environments.

The scleritis market research report is one of a series of new reports from The Business Research Company that provides scleritis market statistics, including the scleritis industry's global market size, regional shares, competitors with a scleritis market share, detailed scleritis market segments, market trends and opportunities, and any further data you may need to thrive in the scleritis industry. This scleritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The scleritis market size has grown strongly in recent years. It will grow from $3.60 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the rising prevalence of autoimmune disorders, increased awareness of ocular health, a growing geriatric population, improved access to ophthalmic care, and the expansion of healthcare infrastructure worldwide.

The scleritis market size is expected to see strong growth in the next few years. It will grow to $5.54 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to the increasing prevalence of eye-related health conditions, rising awareness of ocular health, growing healthcare expenditure, expanding ophthalmology research, increasing demand for personalized medicine, and the development of new treatment options. Key trends include the development of targeted biologic therapies, advancements in immunosuppressive drug formulations, innovations in imaging technologies, the adoption of minimally invasive diagnostic tools, the integration of personalized medicine approaches, improvements in drug delivery systems, and AI-driven diagnostic and treatment planning solutions.

The increasing prevalence of autoimmune diseases is expected to drive the expansion of the scleritis market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, perceiving them as foreign threats. The rise in autoimmune diseases is attributed to genetic predispositions, environmental influences, lifestyle changes, and improved diagnostic awareness. These conditions contribute to scleritis by triggering an inflammatory immune response that mistakenly targets scleral tissue, leading to pain and redness. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Consequently, the growing incidence of autoimmune diseases is fueling the expansion of the scleritis market.

Leading companies in the scleritis market are developing advanced treatments, such as specialized eye drops, to address inflammation and provide non-invasive therapeutic options. Eye drops are liquid formulations designed for direct ocular application to manage conditions such as irritation, dryness, inflammation, and infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, introduced CYCLOTEARS eye drops in India and globally. This innovative treatment for inflammatory eye diseases utilizes proprietary SEDDS technology, enhancing drug delivery and efficacy. The product represents a significant advancement in managing ocular inflammatory conditions, including dry eye disease (DED), ocular myositis, and scleritis.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition grants Regeneron access to an advanced ocular gene therapy delivery system, accelerating its progress toward clinical applications. By integrating Oxular's proprietary technologies, Regeneron aims to enhance therapeutic precision and drive innovation in eye care. Oxular Limited, a UK-based biotech company, specializes in developing drug and device treatments for eye disorders, including scleritis.

Major players in the scleritis market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Fresenius Kabi USA LLC, Sun Pharmaceutical Industries Ltd., Perrigo Company, Horizon Therapeutics plc, Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Alvogen, Accord Healthcare, West-Ward Pharmaceuticals, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Zydus Pharmaceuticals Inc.

North America was the largest region in the scleritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in scleritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the scleritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The scleritis market consists of revenues earned by entities by providing services such as ultrasound, biologic therapies, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleritis market includes sales of ophthalmoscopes, nonsteroidal anti-inflammatory drugs, antibiotics, eye shields or patches, and cold or warm compress kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Scleritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on scleritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for scleritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The scleritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Scleritis Market Characteristics

3. Scleritis Market Trends And Strategies

4. Scleritis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Scleritis Growth Analysis And Strategic Analysis Framework

6. Scleritis Market Segmentation

7. Scleritis Market Regional And Country Analysis

8. Asia-Pacific Scleritis Market

9. China Scleritis Market

10. India Scleritis Market

11. Japan Scleritis Market

12. Australia Scleritis Market

13. Indonesia Scleritis Market

14. South Korea Scleritis Market

15. Western Europe Scleritis Market

16. UK Scleritis Market

17. Germany Scleritis Market

18. France Scleritis Market

19. Italy Scleritis Market

20. Spain Scleritis Market

21. Eastern Europe Scleritis Market

22. Russia Scleritis Market

23. North America Scleritis Market

24. USA Scleritis Market

25. Canada Scleritis Market

26. South America Scleritis Market

27. Brazil Scleritis Market

28. Middle East Scleritis Market

29. Africa Scleritis Market

30. Scleritis Market Competitive Landscape And Company Profiles

31. Scleritis Market Other Major And Innovative Companies

32. Global Scleritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Scleritis Market

34. Recent Developments In The Scleritis Market

35. Scleritis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기